927203-28-9

Basic information

• Product Name: (8aR)-3-(broMoMethyl)-3-Methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione
• Synonyms: (8aR)-3-(broMoMethyl)-3-Methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione
• CAS NO: 927203-28-9
• Molecular Weight: 0
• Mol File: 927203-28-9.mol
• Article Data: 37

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (8aR)-3-(broMoMethyl)-3-Methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (8aR)-3-(broMoMethyl)-3-Methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione(927203-28-9)
• EPA Substance Registry System: (8aR)-3-(broMoMethyl)-3-Methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione(927203-28-9)

Safety Data

• Hazardous Substances Data: 927203-28-9(Hazardous Substances Data)

Usage

General Description

The chemical compound "(8aR)-3-(broMoMethyl)-3-Methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione" is a heterocyclic organic compound that contains a bromomethyl group and a methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione moiety. It is a potentially important compound due to its structural and functional properties. The bromomethyl group can serve as a reactive site for chemical modifications, while the methyltetrahydro-1H-pyrrolo[2,1-c][1,4]oxazine-1,4(3H)-dione moiety is a unique and complex ring system that may have pharmaceutical or biological activity. Further studies and research are needed to fully understand and exploit the potential uses of this compound.

Upstream product

• 106089-24-1 (2R)-1-methacryloylpyrrolidin-2-carboxylic acid 
• 344-25-2 D-Prolin 
• 147-85-3 L-proline 
• 51161-88-7 N-methacryloyl-L-proline 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 261904-39-6 (2R)-3-bromo-2-hydroxy-2-methylpropanoic acid 
• 60-29-7 diethyl ether 
• 920-46-7 Methacryloyl chloride 

Downstream Products

• 106089-20-7 (S)-(-)-3-bromo-2-hydroxy-2-methylpropanoic acid 

Relevant articles and documents

Meta -Non-flat substituents: A novel molecular design to improve aqueous solubility in small molecule drug discovery

Aqueous solubility is a key requirement for small-molecule drug candidates. Here, we investigated the regioisomer-physicochemical property relationships of disubstituted benzenes. We found that meta-isomers bearing non-flat substituents tend to possess the lowest melting point and the highest thermodynamic aqueous solubility among the regioisomers. The examination of pharmaceutical compounds containing a disubstituted benzene moiety supported the idea that the introduction of a non-flat substituent at the meta position of a benzene substructure would be a promising approach for medicinal chemists aiming to improve the thermodynamic aqueous solubility of drug candidates, even though it might not be universally effective. This journal is

Synthetic method for (2R)-3-bromo-2-hydroxy-2-methylpropionic acid

The invention belongs to the technical field of compound synthesis, and in particular relates to a synthetic method for (2R)-3-bromo-2-hydroxy-2-methylpropionic acid. Preparation of methacryloyl-D-proline comprises the following steps: uniformly mixing D-proline, NaOH, MTBE and resorcinol under stirring at 5-20 DEG C, adding methacryloyl chloride dropwise, performing uniform stirring at 15-25 DEGC, allowing the uniformly-stirred material to stand for layering, and taking an upper-layer organic phase to obtain the methacryloyl-D-proline. The method provided by the invention has short synthetictime and is convenient to operate, and the (2R)-3-bromo-2-hydroxy-2-methylpropionic acid has stable quality.

SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF

This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedys disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.